SEC Tracker
Get the app

Medifast MED

Medifast reports $17.51M net loss

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $72.05M for Q3 2026
  2. Net loss: $17.51M for Q3 2026
  3. Diluted EPS: -$1.57 for Q3 2026
  4. Cash and equivalents: $58.37M as of Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Medifast files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Revenue$72.05M$76.38M−5.7%
Operating income and margin−$19.36M · -26.9%−$4.33M · -5.7%−347%, margin −21.2 pts
Net income−$17.51M−$3.1M−465%
Operating cash flow$3.3M$1.7M+94%
Cash$58.37M$71.91M−19%

Similar companies

Companies of similar size in SIC 2090 and related industry codes: the same peer list as the financial tables.

  1. Farmer Brothers FARM
  2. Utz Brands UTZ public float $912M, Jun 29, 2025
  3. Coffee Holding JVA public float $17M, Apr 30, 2025, over 18 months old
  4. McCormick MKC
  5. Top Wealth Group Holding TWG

Data on this page was fetched . The filing on SEC.gov is the record.